The fluoroquinolones are promising new antituberculous agents. A randomized controlled trial of 200 adult patients with sputum smear-positive pulmonary tuberculosis was conducted in Tanzania. Patients received either a trial regimen (HRC) consisting of isoniazid (300 rng), rifampin (600 mg), and ciprofloxacin (750 mg) or a control regimen (HRZE) consisting of isoniazid (300 mg), rifampin (600 mg), pyrazinamide (25 mg/kg), and ethambutol (15 mg/kg). The 168 evaluable patients all had negative smears and cultures by month 6, but the time to conversion to negativity was longer for the HRC group than for the HRZE group because of the poor response of patients infected with human immunodeficiency virus (HIV) to the HRC regimen. Relapse was more frequent in the HRC group. The sterilizing activity of ciprofloxacin does not appear to be equal to that of the combination of pyrazinamide and ethambutol, but the difference in outcome was significant only among HIVinfected patients.
In this new era, the need for effective new antituberculous drugs is becoming increasingly acute. The fluoroquinolones are widely regarded as being among the most promising new antituberculous agents. Of these, ciprofloxacin [9] [10] [11] and ofloxacin [12, 13] have received the most attention so far, although newer drugs such as sparfloxacin [14] and levofloxacin [IS] also appear promising.
Fluoroquinolones are rapidly absorbed and have a high bioavailability. After administration, a single 750-mg oral dose of ciprofloxacin results in a peak serum concentration of 3.41 mg/ L [16] . The MIC of ciprofloxacin for M. tuberculosis ranges from~O.5 mg/L to I mg/L [17] , a level that compares favorably with the achievable serum levels. In addition, the concentration of ciprofloxacin within alveolar macrophages is several times higher than that of other fluoroquinolones [18] .
The clinical data justifying the use of fluoroquinolones to treat human TB remain sparse. Much of the available data come from small, nonrandomized trials in which a fluoroquinolone has been given as a last resort to patients who have failed to respond to standard agents. Nevertheless, the available data suggest that both ciprofloxacin [10, 11] and ofloxacin [12, 13] can be effective in the treatment of human IB. Fluoroquinolones have been successfully used both in the treatment of MDR-TB [12] and in cases where adverse drug reactions, such as hepatotoxicity, have limited the use of standard agents [19] .
We report the results of a randomized controlled trial involving 200 Tanzanian patients with pulmonary T8 who received ciprofloxacin in combination with antituberculous agents. We have previously reported results for 20 of these patients after the first 2 months of treatment; these results included detailed determinations of the fall in sputum colony-counts during this period [20] .
Patients and Methods
Patient population. Participants were recruited from among newly admitted patients with suspected TB who presented to Kibongoto National Tuberculosis Hospital, Kilimanjaro region, Tanzania between July 1990 and February 1992. All patients over the age of 18 whose clinical and radiological presentations were consistent with pulmonary TB were considered for recruitment. Patients were not included unless acidfast bacilli were present in the sputum on direct fluorescent microscopy (i.e., smear-positive cases). Patients with a history of treatment for TB or of other exposures to any of the study drugs were excluded, as were patients with cultures positive for mycobacteria other than M tuberculosis or for isolates of M. tuberculosis that were resistant to any of the study drugs. Further exclusion criteria included severe renal disease, hepatic disease, or cardiovascular disease; pregnancy or lactation; a history of adverse reaction to one of the study drugs; epilepsy; and concomitant treatment with theophylline. Patients with severe TB who were considered unlikely to survive despite treatment were also excluded.
Study design and drug regimens. This study was an open, randomized, controlled clinical trial of two drug regimens: a trial regimen consisting of isoniazid, rifampin, and ciprofloxacin (HRC) vs. a control regimen consisting of isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE). For the trial regimen, isoniazid (300 mg) and rifampin (600 mg) were given daily for 6 months in combination with ciprofloxacin (750 mg), which was given daily for the first 4 months. For the control regimen, isoniazid (300 mg) and rifampin (600 mg) were given daily for 6 months, together with pyrazinamide (25 mg/kg), which was given daily for the first 4 months and ethambutol (15 mg/kg), which was given daily for the first 2 months.
The randomization scheme was generated by a computer program with use of a block size of 10 patients, such that five patients received each treatment regimen per block. Treatment instructions were contained within sealed envelopes.
A formal sample-size calculation was not possible, as no reliable estimate was available for the efficacy ofeither regimen in this population, which included a significant proportion of HIV-infected individuals. A target size of 200 patients was set for the study; this was considered to be the largest attainable sample size on the basis of expected rates of recruitment and available resources.
Drug administration. All drugs were given orally once a day in the morning. To ensure compliance, patients were to be admitted to the hospital for the first 4 months of treatment. Compliance with medication was further ensured by the presence of nursing staff who verified that patients actually swallowed their allocated medication.
Pretreatment assessment. A detailed medical history was obtained on admission; this process was facilitated by the presence of a medical assistant (L.U.) fluent in both English and Swahili. Symptom severity for cough and sputum production were recorded with use of a predefined scoring scheme. Physical examinations, including the measurement of height and weight, were performed, and chest radiographs were obtained.
Sputum samples were obtained prior to treatment, and direct fluorescent smears of the samples were examined. The samples were then transported to the well-equipped tuberculosis laboratory (supported by the International Union Against Tuberculosis and Lung Diseases) of the nearby Kilimanjaro Christian Medical Centre (Moshi, Tanzania) and processed the same day. Sputum volumes were generally large, and approximately half of each sputum sample was used for culture. After a decontamination-homogenization procedure was performed with an equal volume of 4% NaOH, two Lowenstein-Jensen (LJ) slants containing glycerol or pyruvate were inoculated with the sputum precipitate and cultured at 37°C. Isolates were identified as M tuberculosis if they failed to grow at 25°C and on LJ slants containingp-nitrobenzoate. Drug susceptibility testing was performed on all cultures using the resistance ratio method [21] . Subcultures of isolates were prepared on LJ slants, and transported to the Public Health Laboratory Service Regional Tuberculosis Centre (Dulwich, UK) for confirmation of species identification and susceptibility results.
A serum sample was obtained from each patient on admission; an aliquot of each sample was frozen at -20°C and transported to the Royal Free Hospital (London) for determination of HIV serostatus. Sera were screened for the presence of antibodies to HIV-1 by ELISA (Wellcozyme Recombinant HIV-1 ELISA, Murex Diagnostics, Dartford, UK). Positive results were confirmed with use of EIA (Abbott Recombinant HIV-I EIA, Abbott Diagnostics, UK). Patients were recorded as being positive for HIV-I only if both tests were positive. HIV testing and subsequent data analysis were performed in a coded, nonlinked manner.
Follow-up assessments. Patients were followed up at monthly clinic appointments during the 6-month treatment period as well as on regular ward rounds. A sputum sample was obtained during each clinic visit (except during the 5th-month assessment) and sent for direct smear and culture. Clinical and radiological evidence of improvement was also documented at the clinic visits, as were any adverse drug reactions. Further clinical, radiological, and microbiological (smear and culture) assessments were made 2 and 6 months after completion of treatment (month-8 and month-12 assessments, respectively) to detect potential cases of relapse. Strenuous efforts were made to trace patients in the community if they failed to appear for these follow-up appointments.
At the completion of the study, all radiographs were transported to the Royal Free Hospital and independently reviewed by two radiologists (J.G. and L.B.). Each lung field was divided into three zones for the purposes of reporting the findings. The radiologists were unaware of any of the clinical details of the cases.
Outcome measures and statistical analysis. Bacteriologic response (sputum smear results or culture results, assessed as positive or negative) at month 6 was the primary endpoint. Secondary endpoints were time (in months) from admission until the first negative results of sputum smears and cultures were obtained and bacteriologic response at month 12. In addition, a general assessment of clinical response, which was based on regression of the symptoms, signs, and radiological changes, was performed by one of the authors (N.K.) at month 6 and month 12 with use of the categories "completely successful," "improvement," or "failure." An assessment of "overall treatment response" at month 12, which included clinical response and microbiological response, was also made based on these categories. These assessments were included as secondary endpoints.
Continuous variables were tested for normality by means of the Shapiro-Wilk test and were compared by means of the Student's t-test if a normal distribution was observed. Variables such as time to a negative smear or a negative culture, which did not have a normal distribution, were tested with use of the Wilcoxon's rank sum test. Categorical variables were compared in two-by-two contingency tables with use of Fisher's exact test, while ordered categorical variables were compared with use ofthe Wilcoxon rank sum test. A P value of~.05 indicated statistical significance. All statistical tests were two-sided. Outcome was assessed seperately for patients infected with HIV and those not infected with HIV (this approach had been decided upon before the analysis was done).
Results
A total of 200 patients with positive sputum smears were recruited. Sputum cultures were positive for M. tuberculosis for 193 patients, and they were positive for mycobacteria other than M. tuberculosis for two patients (one Mycobacterium fortuitum isolate and one unidentified isolate) and negative for five patients. Drug susceptibility results were obtained in Tan Ninety-eight patients were randomized to the HRZE regimen, and 102 were randomized to the HRC regimen. Thirtytwo patients were subsequently excluded from the analysis; thus 168 patients (86 in the HRZE arm and 82 in the HRC arm) remained. The 12 HRZE patients excluded from the analysis were omitted for the following reasons: inconclusive radiological evidence of tuberculosis on admission (one patient); primary drug resistance (one); cultures positive for non-tuberculosis mycobacteria (one); failure to complete 6 months of treatment (six); or receipt of a nonprotocol drug regimen (three). Twenty patients were excluded from the HRC arm because ofprimary drug resistance (two patients), cultures positive for non-tuberculosis mycobacteria (one), failure to complete 6 months of treatment (nine) or receipt of a nonprotocol drug regimen (eight). Baseline clinical characteristics. Table I shows the baseline clinical characteristics of the patients on admission. The two treatment groups were well matched in terms of the clinical and radiological parameters evaluated, with no statistically significant differences between the groups.
Bacteriological response during treatment. All patients' smears and cultures became negative by month 6, and thus the outcome was successful according to the primary endpoint. The time in months from admission to the first negative result (for both smears and cultures) was longer for patients in the HRC group than for those the HRZE group, and these differences were statistically significant (table 2; P = .02). However, when patients were stratified by HIV status, it emerged that patients without HlV infection had a similar response to the two regimens in terms of time to negative smears and cultures, while HIV-infected patients treated with the HRC regimen had a poorer response than those treated with the HRZE regimen (table 2). Thus the difference in overall response between the two regimens was mainly accounted for by the poor response of HIV-infected patients to the HRC regimen. The striking influence of HIV status on time to sputum culture conversion is clearly illustrated by figure I, which shows the percentage of patients whose cultures remained positive each month. Relapse after treatment. Eighty-one (94%) of 86 patients in the HRZE group and 75 (91%) of 82 patients in the HRC group were successfully followed up for repeated clinical and microbiological assessments 6 months after completing treatment (month 12); eight of these patients missed the assessment in month 8. Two patients died during the 6-month follow-up period (both were in the HRZE group), but neither of these deaths was considered to be related to tuberculosis or antituber- • In both cases, this was the development of isoniazid resistance; another patient's isolate had primary resistance to streptomycin, which was also detected in the isolate causingthe relapse. culous chemotherapy. The remaining 10 patients from both groups who were not followed up failed to keep their appointments and could not be traced in the community. Table 3 shows the relapse rates associated with the two regimens, as assessed by sputum culture results during the 6-month follow-up period. Seven (9.3%) of the 75 patients given the HRC regimen relapsed, compared with none of the 81 patients treated with the HRZE regimen (P = .005; Fisher's exact test). Three of the relapses were detected in month 8 on examination of a sputum sample, and four were detected in month 12. There was a tendency toward a higher relapse rate (12%) among HIV-infected patients than among those without HIV infection (8%), but the numbers were small and statistical differences could not be detected. Six of these seven patients who relapsed also had positive smears, and the seventh patient's smear subsequently became positive. Of these seven patients, five had radiological evidence of relapse, and two had radiological evidence of marked residual disease. We are aware of three additional patients (two in the HRC group and one in the HRZE group) whose cultures became positive after the assessment in month 12, and genuine relapse was again confirmed by sputum smear results and radiological findings. The seven patients who relapsed during the follow-up period were all infected with M. tuberculosis isolates that were initially susceptible to the study drugs used, although one isolate was resistant to streptomycin. These isolates were tested for secondary resistance. The isolates from two patients developed resistance to isoniazid, and the isolate from one patient remained resistant to streptomycin but did not develop new drug resistance; the isolates from the remaining patients remained fully susceptible (table 3) . These results were all confirmed by the PHLS Tuberculosis Reference Laboratory.
Clinical response and overall treatment response. There were no statistically significant differences between the two groups in terms of clinical response at months 6 or 12. Assessments of overall treatment response at month 12 were available for 73 patients in the HRC group and 77 patients in the HRZE group and showed a higher rate of failure in the HRC group than in the HRZE group (7/73 vs. 1/77, respectively; P = .011).
Discussion
The fluoroquinolones are increasingly being used as secondline antituberculous agents in clinical circumstances including the presence ofMDR-TB [22] , or drug-induced hepatotoxicity [19] . Despite the use of fluoroquinolones (principally ciprofloxacin and ofloxacin) in the treatment ofhuman tuberculosis, data on the efficacy of these drugs is still limited. The study presented herein represents one of the first large, randomized comparisons of a regimen containing ciprofloxacin with a traditional short-course regimen.
Antituberculous drugs are generally evaluated in terms of their early bactericidal activity and their sterilizing activity. Assessments of early bactericidal activity measure the ability of a drug to swiftly kill rapidly-growing tubercle bacilli. Assessments of sterilizing activity, by contrast, measure the ability of a drug to kill all, or virtually all, of the bacilli present. Sterilizing activity is assessed in humans on the basis of the culture conversion rate after 2 months of treatment as well as the rate of relapse after treatment is completed [23] .
We observed a slower rate of culture conversion and a higher relapse rate in the HRC group than in the HRZE group, indicating that ciprofloxacin, at a dose of 750 mg daily, is not capable of providing equal sterilizing power to the combination of pyrazinamide and ethambutol. This difference in outcome is likely to have been largely due to differences in response to ciprofloxacin and pyrazinamide, as ethambutol has poor sterilizing activity [23] . These results are consistent with our preliminary observations regarding the sterilizing activities of the HRC regimen and HRZE regimen, which were obtained by examining the fall in cfus per milliliter ofsputum for 20 patients during the first 2 months of treatment [20] .
We cannot entirely exclude the possibility that some of the cases classified as relapses were in fact cases of reinfection rather than relapse. However, there is no apparent reason why reinfections should have clustered in the HRC treatment arm. In addition, the higher relapse rate in the HRC group correlates with the slower conversion rates for smears and cultures, suggesting that these cases were indeed predominantly relapses rather than reinfections.
Although the overall treatment response associated with the HRC regimen was inferior to that associated with the HRZE regimen in our study, the difference in response was only marked for HIV-infected patients. If non-HIV-infected patients only are considered, there were no statistically significant differences in outcome between the groups. However, relapse rates were higher (8%) with the HRC regimen than with the HRZE regimen (0); this difference barely failed to achieve statistical significance (P = .06). Interpretation of these results is complicated by the necessity of giving other drugs in combination with ciprofloxacin.
In the second study by the East AfricanlBritish Medical Research Council [24] , the isoniazid/rifampin combination alone produced rates of culture conversion (64% were negative at month 2) and relapse (5% had relapsed at month 12) that are similar to those we observed for non-Hl'V-infected patients treated with the HRC regimen (75% of cultures were negative at month 2, and 8% of patients had relapsed at month 12). It is therefore possible that ciprofloxacin did not contribute substantially to the sterilizing activity of the HRC regimen. This finding should not be interpreted as indicating that ciprofloxacin lacks antituberculous activity, but rather that the addition of ciprofloxacin may not significantly increase the already powerful sterilizing action of the isoniazid/rifampin combination. Streptomycin and ethambutol are certainly useful antituberculous drugs, but when added to a 6-month regimen of isoniazid/rifampin, they add little to its sterilizing action [24, 25] .
We have previously shown that ciprofloxacin is effective in terms of early bactericidal activity, resulting in an 89% reduction in mean cfus per milliliter of sputum when given as monotherapy at a dose of750 mg daily for 7 days [20] . Ciprofloxacin may therefore be best considered an early bactericidal agent rather than a sterilizing drug in combination regimens. Isoniazid, ethambutol, and streptomycin have good early bactericidal activity but poor sterilizing action [23] . One can speculate that ciprofloxacin may be a potential alternative to these drugs, although our study did not address this question directly.
It should be noted that we administered ciprofloxacin at a daily dosage of 750 mg. We chose this relatively low dose em 1996; 22 (May) because of the limited data regarding long-term f1uoroquino-lone therapy at the time that this study was planned. Higher daily doses of ciprofloxacin (1,000 mg or 1,500 mg) for the treatment of TB have been suggested more recently [22, 26] . It may be that such doses will prove to be more effective in terms of sterilizing activity.
The emergence of isoniazid resistance in two patients (3%) receiving the HRC combination is interesting in that this rate of secondary isoniazid resistance is higher than the rate that would be expected with an isoniazid/rifampin combination alone [24] . Antagonism of rifampin by ciprofloxacin is one possible explanation for this result, although it may simply be a chance occurrence, given the small numbers.
We have previously reported a detailed analysis of the safety profile of the HRZE regimen, compared with that of the HRC regimen, for the first 160 patients enrolled in this trial [27] . The number, severity, and nature of the adverse events experienced by the patients taking the two regimens were similar, and overall, the HRC regimen was well tolerated. Analysis of the data for all 200 patients enrolled in the study (data not shown) does not alter these conclusions.
The marked influence of HIV serostatus on the outcome of treatment that was observed in our study is interesting. Cellmediated immunity plays a central role in host defense against M. tuberculosis infection, so the potential for HIV infection to affect treatment outcome for patients with TB is readily apparent. Despite this factor, the treatment response ofHIV-infected patients with drug-susceptible M. tuberculosis isolates has largely been favorable when modem short-course regimens containing rifampin and pyrazinamide have been administered [28, 29] . Results from Africa, where cheaper regimens that do not include rifampin have been used, are less encouraging. In Zaire, the overall treatment failure rate was higher for HIVinfected patients than for non-HIV-infected patients, mainly because relapse rates were increased three-fold [30] . In Kenya, the recurrence rate for TB was found to be 34 times higher among patients with HIV infection than among those without HIV infection [31] . Our results are consistent with the view that a good treatment response can be obtained in HIV-infected patients, but use ofa combination ofrifampin and pyrazinamide appears to be essential.
Cost is an important consideration with antituberculous regimens, particularly in developing nations. Ciprofloxacin is a relatively expensive drug that may not be affordable in developing countries such as Tanzania. However, similar arguments have been used with regard to rifampin, whereas studies have shown that short-course regimens containing rifampin are actually more cost-effective overall than are the older, less effective, cheaper regimens [32, 33] . There is a real need for new second-line agents in both the developed countries and developing countries. A highly effective but relatively expensive new drug might even prove to be cost-effective as a first-line agent, although we would not advocate ciprofloxacin for such a role at present.
Further studies are needed to define the role of ciprofloxacin and other f1uoroquinolone agents in the treatment of TB. In such studies, a variety of combination regimens, as well as the efficacy and safety of high-dose ciprofloxacin, should be examined. Longer durations of therapy are also worth exploring, as indicated by the successful use of ofloxacin as a substitute for ethambutol in a 9-month treatment regimen [13] . It is essential that differences in outcome for both HIV-infected and non-HIV-infected patients be evaluated in any future studies. Such clinical trials of new drugs must be accompanied by operational studies and tuberculosis program activities aimed at improving case-finding, ensuring drug availability and quality, and enhancing compliance with existing treatment protocols, as deficiencies in these areas remain the main obstacles to improving the control of TB in many areas of the world.
